Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis | Zendy

Elena Gibson | Zendy; Melissa Pender | Zendy; Michael Angerbauer | Zendy; Craig Cook | Zendy; Barbara Jones | Zendy; Adam M. Spivak | Zendy; Emily S Spivak | Zendy; Sankar Swaminathan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis

Author(s) -

Elena Gibson,

Melissa Pender,

Michael Angerbauer,

Craig Cook,

Barbara Jones,

Adam M. Spivak,

Emily S Spivak,

Sankar Swaminathan

Publication year - 2021

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofab176

Subject(s) - medicine , ocrelizumab , multiple sclerosis , covid-19 , viral shedding , coronavirus , immunology , monoclonal antibody , virology , disease , antibody , infectious disease (medical specialty) , rituximab

We describe a case of prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a patient receiving ocrelizumab for multiple sclerosis. Viral RNA shedding, signs, and symptoms persisted for 69 days with resolution after administration of convalescent plasma and antiviral therapy. This case suggests risk for persistent SARS-CoV-2 infection in patients treated with anti-CD-20 monoclonal antibodies and supports a role for humoral immunity in disease resolution.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research